1. Inicio
  2. Proyectos y Estudios
  3. Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del barzolvolimab en pacientes con urticaria espontánea crónica que siguen presentando síntomas a pesar de recibir tratamiento con antihistamínicos H1 (EMBARQ - CSU2).

Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del barzolvolimab en pacientes con urticaria espontánea crónica que siguen presentando síntomas a pesar de recibir tratamiento con antihistamínicos H1 (EMBARQ - CSU2).

Datos básicos

Código:
CDX0159-13
Protocolo:
CDX0159-13
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2024
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

CELLDEX THERAPEUTICS INC

Resultados del Ensayo Clínico

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab.

Lasheras-Perez, Miguel Antonio; (...); Ibanez-Echevarria, Ethel

Article. 10.1111/cod.14774. 2025


A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study

Puig, Lluis; (...); IMPULSE Investigators Grp

Article. 10.1159/000540019. 2024

  • Open Access.

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC).

Chicharro P; (...); Sánchez-Pérez J

Article. 10.1111/cod.14672. 2024


Atypical bullae in hands and trunk: An unusual suspect

Palacios-Diaz, Rodolfo David, Lasheras-Perez, Miguel Antonio, Rodriguez-Serna, Mercedes

Editorial Material. 10.1016/j.eimc.2023.12.010. 2024

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Delusional parasitosis (Ekbom's syndrome).

Mansilla-Polo, M, Martin-Torregrosa, D, Botella-Estrada, R

Article. 10.1016/j.semerg.2024.102423. 2024

  • Open Access.

Dermatologic Consultations for Patients Hospitalized in Non-Dermatologic Wards: Results of a 384-Patient Cross-Sectional Study From a Tertiary Referral Hospital

Mansilla-Polo, M.; (...); Botella-Estrada, R.

Letter. 10.1016/j.ad.2024.10.030. 2024

  • Open Access.

Dermatological toxicities of talquetamab, a new bispecificantibody: case series and literature review

Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael

Letter. 10.1111/ddg.15502_g. 2024


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study

Duc Binh Phan; (...); Yiu, Zenas Zee Ngai

Meeting Abstract. 2024


Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study.

Phan, Duc Binh; (...); Yiu, Zenas Z N

Article. 10.1093/bjd/ljae454. 2024

  • Open Access.

Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.

Mansilla-Polo M; (...); Botella-Estrada R

Article. 10.1016/j.abd.2024.04.004. 2024

  • Open Access.

Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

Gutzmer, Ralf; (...); Hauschild, Axel

Article. 10.1186/s12885-024-13101-z. 2024

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

Nodular hidradenoma: Case report and brief literature review.

Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael

Article. 10.1016/j.patol.2025.100801. 2025


Oral Ruxolitinib could Increase the Aggressiveness of Cutaneous Squamous Cell Carcinomas: A 6-Patient Series

Lasheras-Perez, M. A.; (...); Botella-Estrada, R.

Letter. 10.1016/j.ad.2023.07.035. 2025


Paraoxonase I Activity and Its Relationship with Nutrition in Amyotrophic Lateral Sclerosis.

Proaño B; (...); de la Rubia Ortí JE

Article. 10.3390/antiox13081021. 2024

  • Open Access.

Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023.

Pesqué D; (...); Giménez-Arnau AM

Article. 10.1111/cod.14702. 2024

  • Open Access.

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.

Magaz, Marta; (...); Garcia-Pagan, Juan Carlos

Article. 10.1016/j.jhep.2024.07.035. 2024


Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Martorell A; (...); Magdaleno-Tapial J

Article. 10.1016/j.ad.2024.10.042. 2024


Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast

Mansilla-Polo, M.; (...); Botella-Estrada, R.

Letter. 10.1016/j.ad.2024.10.025. 2024

  • Open Access.

Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.

Lasheras-Perez MA; (...); Botella-Estrada R

Article. 10.1016/j.ad.2024.10.003. 2025


Safety of biosimilars compared with originator adalimumab for psoriasis: a multinational cohort study

Phan, Duc Binh; (...); Yiu, Zenas

Meeting Abstract. 10.1093/bjd/ljae360.068. 2024

  • Open Access.

Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.

Martín-Torregrosa D; (...); Botella-Estrada R

Article. 10.1016/j.ad.2024.10.043. 2024

  • Open Access.

Study of Microsatellite Instability by Immunohistochemistry in a Cohort of Patients With Melanoma

Diaz, Rodolfo David Palacios; (...); Estrada, Rafael Botella

Article. 10.1111/cup.14758. 2025


Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.

Martin-Torregrosa, Daniel; (...); Botella-Estrada, Rafael

Article. 10.1001/jamadermatol.2024.4582. 2024

  • Open Access.

Sustained response to anti-TNF therapy in ASIA syndrome triggered by vaccination and filler.

Martin-Torregrosa, Daniel; (...); Rodriguez-Serna, Mercedes

Letter. 10.1111/ijd.17650. 2025


Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.

Perez-Del-Caz, Maria Dolores; (...); Perez-Plaza, Aranzazu

Article. 10.1016/j.burns.2025.107427. 2025


Campos de estudio

Compartir